Uveitis

Melden Sie sich bitte hier kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.

Zur Anmeldung

AutorIn: Ass.-Prof. Priv.-Doz. Dr. Marion Funk

Leiterin der Ambulanz für Uveitis und intraokulare Entzündungen, Universitätsklinik für Augenheilkunde und Optometrie, Medizinische Universität Wien


1 Becker M.D., Adamus G., Davey M.P., Rosenbaum J.T.: The role of T cells in autoimmune uveitis. Ocul Immunol Inflamm 2000; 8: 93–100
2 Suhler E.B., Smith J.R., Giles T.R. et al.: Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch. Ophthalmol 2009; 127 (6): 819–22
3 Niccoli L., Nannini C., Benucci M. et al.: Long-term efficacy of infliximab in refractory posterior uveitis of Behçet’s disease: a 24-month follow-up study. Rheumatology (Oxford) 2007; 46 (7): 1161–64
4 Yamada Y., Sugita S., Tanaka H. et al.: Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease. Br J Ophthalmol 2010 Mar; 94 (3): 284–8
5 Tynjala P., Lindahl P., Honkanen V. et al.: Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007; 66 (4): 548–50
6 Rudwaleit M., Rødevand E., Holck P. et al.: Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active akylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009; 68 (5): 696–701
7 Simonini G., Taddio A., Cattalini M. et al.: Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res 2011; 63 (4): 612–18
8 Levy-Clarke G., Jabs D.A., Read R.W., Van Gelder R.N.: Expert Panel Recommendations for the Use of Anti-Tumor Necrosis Factor Biologic Agents in Patients with Ocular Inflammatory Disorders. Ophthalmology 2014; 121: 785–96
9 Gueudry J., Wechsler B., Terrada C. et al.: Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet disease. Am J Ophthalmol Dec 2008; 146 (6): 837–44
10 Hatemi G., Silman A., Bang D. et al.: Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease. Ann Rheum Dis Oct 2009; 68 (10): 1528–34
11 Gul A., Tugal-Tutkun I., Dinarello C.A. et al.: IL-1b-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: an open-label pilot study. Ann Rheum Dis 2012; 71 (4): 563–66
12 Muselier A., Bielefeld P., Bidot S. et al.: Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm Oct 2011; 19 (5): 382–3
13 Hirano T., Ohguro N., Hohki S. et al.: A case of Behcet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol Apr 2012; 22 (2): 298–302
14 Hueber W., Patel D.D., Dryja T. et al.: Effects of AIN457, a fully human antibody to IL-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2 (52)
15 Dick A.D., Tugal-Tutkun I., Foster S. et al.: Secukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical Trials. Ophthalmology 2013; 120 (4)
16 Miserocchi E., Pontikaki I., Modorati G. et al.: Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev 2011; 11 (1): 35–9
17 Heiligenhaus A., Miserocchi E., Heinz C. et al.: Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford) 2011; 50 (8): 1390–4
18 Davatchi F., Shams H., Rezaipoor M. et al.: Rituximab in intractable ocular lesions of Behcet’s disease; randomized singleblind control study (pilot study). Int J Rheum Dis 2010; 13 (3): 246–52
19 Pelegrin L., Jakob E., Schmidt-Bacher A. et al.: Experiences with rituximab for the treatment of autoimmune diseases with ocular involvement. J Rheumatol 2014; 41 (1): 84–90
20 Zulian F., Balzarin M., Falcini F. et al.: Abatacept for severe Anti-TNF a refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res 2010; 62 (6): 821–25
21 Kenawy N., Cleary G., Mewar D. et al.: Abatacept: a potential therapy in refractory cases of JIA-associated uveitis. Graefes Arch. Clin Exp Ophthalmol 2011; 249 (2): 297–300
22 Murphy C.C., Ayliffe W.H., Booth A. et al.: Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 2004; 111: 352–56
23 Chauhan S., Kamal A., Thompson R.N. et al.: Rituximab for treatment of scleritis associated with rheumatoid arthritis. Br J Ophthalmol 2009; 93: 984–85


FdR 03|2014

Herausgeber: o. Univ.-Prof. Dr. Josef Smolen, Klinische Abteilung für Rheumatologie, Universitätsklinik für Innere Medizin III, Medizinische Universität Wien
Publikationsdatum: 2014-09-21